This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $284,784 to The Leland Stanford Junior University to support a 5-year research project led by Dr. Michael Binkley. The project aims to develop improved treatment approaches for patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), a rare subtype of Hodgkin lymphoma. The key objectives are to: (1) identify genomic and microenvironmental factors that predict clinical outcomes to optimize therapy, (2) use circulating tumor DNA to genotype NLPHL and establish its utility for disease surveillance, and (3) assess noninvasive testing for inherited coronary artery disease risk. This work will lay the foundation for future clinical trials on de-escalating therapy for low-risk NLPHL patients to reduce treatment-related morbidity and mortality.
Generated 4/1/25, 3:28 AM